Similar articles

• Up the Nose and Down the Windpipe May Be the Path to New and Improved COVID-19 Vaccines.

  Rubin R. Rubin R. JAMA. 2024 Jan 2;331(1):12-14. doi: 10.1001/jama.2023.0644. JAMA. 2024. PMID: 38055302
• Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.

  Lim HX, Arip M, Yahaya AAA, Jazayeri SD, Poppema S, Poh CL. Lim HX, et al. Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024. Front Biosci (Landmark Ed). 2021. PMID: 34856768 Review.
• Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines.

  Rubin R. Rubin R. JAMA. 2021 Nov 2;326(17):1661-1663. doi: 10.1001/jama.2021.18143. JAMA. 2021. PMID: 34647956 No abstract available.
• Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8⁺ T cell responses.

  Ishii H, Nomura T, Yamamoto H, Nishizawa M, Thu Hau TT, Harada S, Seki S, Nakamura-Hoshi M, Okazaki M, Daigen S, Kawana-Tachikawa A, Nagata N, Iwata-Yoshikawa N, Shiwa N, Suzuki T, Park ES, Ken M, Onodera T, Takahashi Y, Kusano K, Shimazaki R, Suzaki Y, Ami Y, Matano T. Ishii H, et al. Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233545 Free PMC article.
• Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

  [No authors listed] [No authors listed] Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007. Drugs R D. 2003. PMID: 12952502 Review.